Lapatinib (TYKERB FCT) 250MG Tablet

TYKERB FCT Tablet contains Lapatinib in a strength of 250mg, serving as a medication primarily prescribed for the treatment of HER2-positive breast cancer, particularly in cases where other treatments have not been effective.

Key Features:

• Breast Cancer Treatment: TYKERB FCT Tablet is indicated for the treatment of HER2-positive breast cancer, a subtype of breast cancer characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein.
• Lapatinib Mechanism of Action: Lapatinib, the active ingredient in TYKERB, is a tyrosine kinase inhibitor that targets both the HER2 and epidermal growth factor receptor (EGFR) pathways, thereby inhibiting tumor cell growth and proliferation.
• HER2-Positive Breast Cancer: TYKERB is specifically indicated for use in patients with advanced or metastatic HER2-positive breast cancer who have received prior treatment with other anti-HER2 therapies, such as trastuzumab (Herceptin).
• Fixed-Dose Combination Tablet: TYKERB FCT Tablet contains a fixed dose of Lapatinib (250mg) in each tablet, simplifying dosing and ensuring consistent medication delivery.
• Oral Administration: Administered orally, usually once daily, TYKERB FCT Tablet offers convenient dosing for patients with breast cancer, allowing them to take their medication at home.
• Combination Therapy: TYKERB may be used in combination with other anticancer therapies, such as chemotherapy or hormonal therapy, to maximize treatment efficacy and improve outcomes in patients with HER2-positive breast cancer.
• Clinical Efficacy: Clinical studies have demonstrated the efficacy of Lapatinib in prolonging progression-free survival and overall survival in patients with HER2-positive breast cancer, particularly when used in combination with other agents.
• Potential Adverse Effects: Common side effects of TYKERB may include diarrhea, rash, nausea, fatigue, and elevated liver enzymes. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of TYKERB as a treatment option for HER2-positive breast cancer should be based on factors such as disease stage, patient’s overall health status, prior treatment history, and treatment goals.